

10/500, 511

=> d his

(FILE 'HOME' ENTERED AT 14:48:43 ON 11 SEP 2006)

FILE 'CAPLUS, BIOSIS, SCISEARCH, LIFESCI, MEDLINE' ENTERED AT 14:49:08 ON 11 SEP 2006

L1 252 S (LIVER OR HEPATIC) (6A) BASEMENT (W) MEMBRANE
L2 401897 S PROTEASE
L3 10 S L1 AND L2
L4 215997 S DETERGENT OR POLYOXYETHYLENE (W) ETHERS OR PROPANE (W) SULFONATE
L5 9 S NONYLPHENOXY (W) POLYETHOXY (W) ETHANOL
L6 1003 S POLYOXYETHYLENESORBITANS OR SODIUM (W) LAURYL (W) SARCOSINATE OR
L7 216780 S L4 OR L5 OR L6
L8 0 S L1 AND L7
L9 5 DUP REM L3 (5 DUPLICATES REMOVED)

=> d au ti so pi ab 1-5 l9

L9 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
IN Badylak, Stephen Francis; Morris, Kenneth Robert
TI Compositions for inhibiting hypersensitivity
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003059284	A2	20030724	WO 2003-US650	20030109
	WO 2003059284	A3	20031231		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003210474	A1	20030730	AU 2003-210474	20030109

AB The present invention is directed to methods, compns., and devices for preventing or inhibiting undesired sensitization reactions of the skin or mucosa caused by a component of a transdermal or transmucosal drug delivery system. A method is provided wherein a matrix composition is administered to intact skin or mucosa of a vertebrate in combination with a transdermal or transmucosal drug delivery system to inhibit sensitization of the skin or mucosa by a component of the delivery system. The invention is also directed to a pharmaceutical composition comprising the transdermal or transmucosal drug delivery system, an effective amount of a drug, and a sensitization inhibitory composition comprising a matrix composition,
and to a delivery device for administration of such a composition. Urinary bladder submucosa was prepared from porcine urinary bladder from a local meat processing plant. The excised urinary bladder was rinsed free of contents, and the superficial layers of the mucosa were removed by mech. delamination. Urinary bladder powder was suspended in extraction buffers (25% containing phenylmethyl sulfonyl fluoride, N-ethylmaleimide, and benzamidine (protease inhibitors) each at 1 mM and vigorously stirred for 24 h at 4°. The extraction mixture was then centrifuged and the supernatant collected.

L9 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
IN Mochitate, Katsumi
TI Method of preparing basement membrane, method of constructing basement membrane specimen, reconstituted artificial tissue using the basement

membrane specimen and process for producing the same
SO PCT Int. Appl., 85 pp.

CODEN: PIXXD2

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

PI	WO 2003026712	A1	20030403	WO 2002-JP9841	20020925
	W: US				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
	JP 2003093050	A2	20030402	JP 2001-292510	20010925
	JP 3785532	B2	20060614		
	JP 2003093053	A2	20030402	JP 2001-292676	20010925
	JP 2003169846	A2	20030617	JP 2002-278243	20020924
	JP 2003169847	A2	20030617	JP 2002-278244	20020924
	EP 1437147	A1	20040714	EP 2002-772905	20020925
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR, BG, CZ, EE, SK				
	US 2004234510	A1	20041125	US 2004-809218	20040325

AB A basement membrane is formed by culturing cells on a substrate wherein the basal face of cells capable of forming a basement membrane has been coated with a polymer having a sugar chain capable of localizing a receptor having an effect of accumulating basement membrane-constituting components. The basement membrane specimen is constructed by treating cells, which are capable of forming a basement membrane and have been adhered to a support via the basement membrane, with a surfactant to solubilize lipid components of the cells and solubilizing proteins remaining on the basement membrane surface with the use of a mixture of an alkali solution with a protease inhibitor. An artificial tissue is obtained by inoculating and culturing desired cells capable of forming a basement membrane. Using a hydrophobic bond adsorption polymer having a linear carbon skeleton with a hydrophobic nature and a functional group capable of reacting with a protein (for example, an alternate copolymer of Me vinyl ether with maleic anhydride), a protein support is tentatively adhered to a plastic surface and a basement membrane specimen or an artificial tissue is formed thereon. Thus, the protein support carrying the basement membrane specimen or the artificial tissue thereon can be phys. separated from the plastic surface when needed. Sugar chain-containing vinyl polymer (PV-GluNAc, PV-CA, or PV-Lam) was applied to fibrous collagen gel formed on a polyethylene terephthalate membrane in a culture well for culture of human pulmonary artery vascular endothelial cells to obtain a basement membrane.

L9 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1

AU Maru, Yoshiro; Hirosawa, Hiroshige; Shibuya, Masabumi

TI An oncogenic form of the Flt-1 kinase has a tubulogenic potential in a sinusoidal endothelial cell line

SO European Journal of Cell Biology (2000), 79(2), 130-143

CODEN: EJCBND; ISSN: 0171-9335

AB The authors have previously reported a constitutively activated form of the Flt-1 kinase (BCR-FLTm) molecularly engineered based on the structural backbone of the activated Tyr kinase BCR-ABL. Here the authors show that it can induce not only growth stimulation but also tubulogenic differentiation of non-tubulogenic NP31 (non parenchymal) sinusoidal endothelial cells of rat liver in basement membrane matrix. Tubules formed in vitro were accompanied by fenestration structures and allowed circulation when transplanted into syngeneic animals. This biol. response was not observed in other activated forms of kinases constructed in a similar fashion, which include Trk (BCR-TRK), KDR (BCR-KDR), and the parental BCR-ABL. Interestingly, formation of fine tubules was accomplished with lower but not higher expression levels of BCR-FLTm. Compared to NP cells in primary culture NP31 is deficient in expression of $\alpha 1$ integrin subunit, which was restored by expression of BCR-FLTm that had tubulogenic ability. Matrix-induced Tyr phosphorylation of an adaptor protein Shc with

recruitment of Grb-2 was observed even when tubulogenesis was nearly completed at G1 stage of the cell cycle in 2-3 wk. Activation of matrix metalloproteinase 2 (MMP-2) and expression of urokinase type plasminogen activator (uPA) was observed with cellular invasion into matrix at the depth of 200-300 μ m. Inhibitors for MAP kinase activator MEK1 and for Ser proteases showed deleterious effects on the tubulogenesis. The authors suppose that matrix ligand-induced integrin signals cooperate with a low level of Flt-1 kinase activity to promote tubulogenic behaviors of endothelial cells in this system.

L9 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN

AU Ogata, Yutaka; Shirouzu, Kazuo

TI Prediction for liver metastasis from colorectal cancer using basement membrane related factors

SO Igaku no Ayumi (1996), 179(4), 219-222

CODEN: IGAYAY; ISSN: 0039-2359

AB A review, with 6 refs., on the roles of proteases in liver metastasis of colon cancer by degrading basement membrane, and higher expression ratio of matrix metalloproteinase 9 (MMP-9) in colon cancer with liver metastasis than that without the metastasis. Combination of the expression pattern of MMP-9 and tissue inhibitors of metalloproteinase 1 (TIMP-1) is more sensitive index for liver metastasis of colon cancer than MMP-9 alone. Serine proteases such as urokinase type plasminogen activator may play some roles in the metastasis with interaction with MMPs. Formation of basement membrane exhibits strong correlation with the liver metastasis.

L9 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2

AU Arthur, Michael J. P.; Friedman, Scott L.; Roll, F. Joseph; Bissell, D. Montgomery

TI Lipocytes from normal rat liver release a neutral metalloproteinase that degrades basement membrane (type IV) collagen

SO Journal of Clinical Investigation (1989), 84(4), 1076-85

CODEN: JCINAO; ISSN: 0021-9738

AB A proteinase is reported that degrades basement-membrane (type IV) collagen and is produced by the liver. Its cellular source is lipocytes (fat-storing or Ito cells). Lipocytes were isolated from normal rat liver and established in primary culture. The cells synthesize and secrete a neutral proteinase, which by gelatin-substrate gel electrophoresis and gel filtration chromatog., has a mol. mass of 65 kDa. The enzyme is secreted in a latent form and is activated by p-aminophenylmercuric acetate but not by trypsin. Enzyme activity in the presence of EDTA is restored selectively by Zn and is unaffected by serine-protease inhibitors. In assays with radiolabeled soluble substrates, it degrades native type IV (basement membrane) collagen but not interstitial collagen types I or V and exhibits no activity against laminin or casein. At temps. causing partial denaturation of soluble collagen in vitro, it rapidly degrades types I and V. Thus, it is both a type IV collagenase and gelatinase. The enzyme may play a role in initiating breakdown of the subendothelial matrix in the Disse space as well as augmenting the effects of collagenases that attack native interstitial collagen.

=>

Refine Search

Search Results -

Terms	Documents
L1 with L4	3

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

L6 ▲
▼

Search History

DATE: Monday, September 11, 2006
 [Purge Queries](#)
 [Printable Copy](#)
 [Create Case](#)

Set
Name Query
 side by
 side

Hit
Count
 Set
Name
 result
 set

DB=PGPB,USPT; PLUR=YES; OP=AND

L6 11 with l4

3 L6

L5 l3 and L4

4 L5

L4 detergent or polyoxyethylene adj ether or propane adj sulfonate or
 nonyphenoxy adj polyethoxy adj ethanol or polyoxyethylenesorbitans or
 sodium adj lauryl adj sarcosinate or alkyl adj glucoside

120427 L4

L3 11 with L2

4 L3

L2 protease

81003 L2

L1 (liver or hepat) near6 (basement adj membrane)

133 L1

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 4 of 4 returned.**

☐ 1. [20050019419](#). 30 Jun 04. 27 Jan 05. Biomaterial derived from vertebrate liver tissue. Badylak, Stephen Francis, et al. 424/553; A61K035/407.

☐ 2. [20040191226](#). 04 Dec 03. 30 Sep 04. Method for repair of body wall. Badylak, Stephen F.. 424/93.7; 424/553 A61K035/407.

☐ 3. [20040187877](#). 04 Dec 03. 30 Sep 04. Method for repair of liver tissue. Badylak, Stephen F., et al. 128/898; 623/902 A61F002/02.

☐ 4. [20030216812](#). 02 May 03. 20 Nov 03. Vascularization enhanced graft constructs. Badylak, Stephen F.. 623/17.16; 623/1.41 623/23.72 A61F002/44 A61F002/06.

[Generate Collection](#)[Print](#)

Terms	Documents
L1 with L2	4

[Prev Page](#)[Next Page](#)[Go to Doc#](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 3 of 3 returned.**

☐ 1. [20050019419](#). 30 Jun 04. 27 Jan 05. Biomaterial derived from vertebrate liver tissue. Badylak, Stephen Francis, et al. 424/553; A61K035/407.

☐ 2. [20040191226](#). 04 Dec 03. 30 Sep 04. Method for repair of body wall. Badylak, Stephen F.. 424/93.7; 424/553 A61K035/407.

☐ 3. [20040187877](#). 04 Dec 03. 30 Sep 04. Method for repair of liver tissue. Badylak, Stephen F., et al. 128/898; 623/902 A61F002/02.

[Generate Collection](#)[Print](#)

Terms	Documents
L1 with L4	3

[Prev Page](#)[Next Page](#)[Go to Doc#](#)